Mark Strobeck's most recent trade in Rockwell Medical Inc was a trade of 6,926 Common Stock done at an average price of $0.8 . Disclosure was reported to the exchange on July 1, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Rockwell Medical Inc | Mark Strobeck | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 0.82 per share. | 01 Jul 2025 | 6,926 | 337,752 (0%) | 0% | 0.8 | 5,679 | Common Stock |
| Rockwell Medical Inc | Mark Strobeck | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 0.82 per share. | 01 Jul 2025 | 6,926 | 337,752 (0%) | 0% | 0.8 | 5,679 | Common Stock |
| Rockwell Medical Inc | Mark Strobeck | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2025 | 308,000 | 308,000 | - | - | Stock Option (Right to Buy) | |
| Rockwell Medical Inc | Mark Strobeck | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2025 | 220,000 | 344,678 (0%) | 0% | 0 | Common Stock | |
| Rockwell Medical Inc | Mark Strobeck | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 1.08 per share. | 01 Apr 2025 | 6,926 | 124,678 (0%) | 0% | 1.1 | 7,480 | Common Stock |
| Rockwell Medical Inc | Mark Strobeck | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.70 per share. | 14 Mar 2025 | 7,333 | 137,705 (0%) | 0% | 1.7 | 12,466 | Common Stock |
| Rockwell Medical Inc | Mark Strobeck | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.77 per share. | 14 Mar 2025 | 6,101 | 131,604 (0%) | 0% | 1.8 | 10,799 | Common Stock |
| Rockwell Medical Inc | Mark Strobeck | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 2.06 per share. | 02 Jan 2025 | 2,163 | 145,038 (0%) | 0% | 2.1 | 4,445 | Common Stock |
| Rockwell Medical Inc | Mark Strobeck | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 3.69 per share. | 01 Oct 2024 | 2,163 | 147,201 (0%) | 0% | 3.7 | 7,971 | Common Stock |
| Rockwell Medical Inc | Mark Strobeck | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.40 per share. | 17 Mar 2024 | 6,101 | 149,364 (0%) | 0% | 1.4 | 8,541 | Common Stock |
| Rockwell Medical Inc | Mark Strobeck | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2024 | 141,560 | 141,560 | - | - | Stock Option (Right to Buy) | |
| Rockwell Medical Inc | Mark Strobeck | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2024 | 100,000 | 155,465 (0%) | 0% | 0 | Common Stock | |
| Windtree Therapeutics Inc | Mark Strobeck | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Aug 2023 | 3,450 | 3,450 | - | - | Stock Option (Right to Buy) | |
| Windtree Therapeutics Inc | Mark Strobeck | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Aug 2023 | 2,300 | 2,300 (0%) | 0% | 0 | Common Stock | |
| Rockwell Medical Inc | Mark Strobeck | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Mar 2023 | 77,105 | 77,105 | - | - | Stock Option (Right to Buy) | |
| Rockwell Medical Inc | Mark Strobeck | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Mar 2023 | 55,465 | 55,465 (0%) | 0% | 0 | Common Stock | |
| Rockwell Medical Inc | Mark Strobeck | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2022 | 400,000 | 400,000 | - | - | Stock Option (Right to Buy) |